GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults
出版年份 2021 全文链接
标题
GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults
作者
关键词
-
出版物
Science Translational Medicine
Volume 14, Issue 627, Pages -
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2021-10-26
DOI
10.1126/scitranslmed.abj1996
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
- (2021) Jianmin Zuo et al. NATURE IMMUNOLOGY
- Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
- (2021) Xuping Xie et al. NATURE MEDICINE
- Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report
- (2021) Kai Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Covid-19: Countries are learning what others paid for vaccines
- (2021) Owen Dyer BMJ-British Medical Journal
- SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8+ T cell responses
- (2021) Benedikt Agerer et al. Science Immunology
- Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2
- (2021) Thomas Thiele et al. BLOOD
- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
- (2021) Wilfredo F. Garcia-Beltran et al. CELL
- Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19
- (2021) Stefania Capone et al. MOLECULAR THERAPY
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
- (2021) Andreas Greinacher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination
- (2021) Jonathan Douxfils et al. THROMBOSIS RESEARCH
- Serum Neutralizing Activity of mRNA-1273 Against SARS-CoV-2 Variants
- (2021) Angela Choi et al. JOURNAL OF VIROLOGY
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
- (2021) Delphine Planas et al. NATURE
- Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
- (2021) Galit Alter et al. NATURE
- BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
- (2021) Jianying Liu et al. NATURE
- Evidence for antibody as a protective correlate for COVID-19 vaccines
- (2021) Kristen A. Earle et al. VACCINE
- Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
- (2021) Takuya Tada et al. mBio
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
- (2020) Alba Grifoni et al. CELL
- Immunology of COVID-19: current state of the science
- (2020) Nicolas Vabret et al. IMMUNITY
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
- (2020) Feng-Cai Zhu et al. LANCET
- Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
- (2020) Pedro M Folegatti et al. LANCET INFECTIOUS DISEASES
- Rapid COVID-19 vaccine development
- (2020) Barney S. Graham SCIENCE
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2020) Feng-Cai Zhu et al. LANCET
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
- (2020) Julian Braun et al. NATURE
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
- (2020) Denis Y Logunov et al. LANCET
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
- (2020) Evan J. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
- (2020) Cheryl Keech et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospects for a safe COVID-19 vaccine
- (2020) Barton F. Haynes et al. Science Translational Medicine
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- (2020) Maheshi N Ramasamy et al. LANCET
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Covid-19 vaccines: delivering protective immunity
- (2020) Herb F Sewell et al. BMJ-British Medical Journal
- Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
- (2017) Jesper Pallesen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization
- (2013) K. M. Quinn et al. JOURNAL OF IMMUNOLOGY
- Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults
- (2013) Shujun Zhang et al. JOURNAL OF MEDICAL VIROLOGY
- Adenovirus-Based Vaccines: Comparison of Vectors from Three Species ofAdenoviridae
- (2010) H. Chen et al. JOURNAL OF VIROLOGY
- International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials
- (2009) T. Christopher Mast et al. VACCINE
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
- (2008) Susan P Buchbinder et al. LANCET
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now